Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleInflammation, Immunopharmacology, and Asthma

Pharmacologic Profile of OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist That Inhibits Mast Cell-Dependent Activation of T Helper 2 Lymphocytes and Eosinophils

Roy Pettipher, Shân L. Vinall, Luzheng Xue, Graham Speight, Elizabeth R. Townsend, Lucien Gazi, Cliff J. Whelan, Richard E. Armer, Mark A. Payton and Michael G. Hunter
Journal of Pharmacology and Experimental Therapeutics February 2012, 340 (2) 473-482; DOI: https://doi.org/10.1124/jpet.111.187203
Roy Pettipher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shân L. Vinall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luzheng Xue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Speight
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Townsend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucien Gazi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cliff J. Whelan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard E. Armer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Payton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Hunter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 340 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 340, Issue 2
1 Feb 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacologic Profile of OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist That Inhibits Mast Cell-Dependent Activation of T Helper 2 Lymphocytes and Eosinophils
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleInflammation, Immunopharmacology, and Asthma

Pharmacological Profile of the Novel DP2 Antagonist OC000459

Roy Pettipher, Shân L. Vinall, Luzheng Xue, Graham Speight, Elizabeth R. Townsend, Lucien Gazi, Cliff J. Whelan, Richard E. Armer, Mark A. Payton and Michael G. Hunter
Journal of Pharmacology and Experimental Therapeutics February 1, 2012, 340 (2) 473-482; DOI: https://doi.org/10.1124/jpet.111.187203

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleInflammation, Immunopharmacology, and Asthma

Pharmacological Profile of the Novel DP2 Antagonist OC000459

Roy Pettipher, Shân L. Vinall, Luzheng Xue, Graham Speight, Elizabeth R. Townsend, Lucien Gazi, Cliff J. Whelan, Richard E. Armer, Mark A. Payton and Michael G. Hunter
Journal of Pharmacology and Experimental Therapeutics February 1, 2012, 340 (2) 473-482; DOI: https://doi.org/10.1124/jpet.111.187203
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Expression of PAR2 in iKera to Model Atopic Dermatitis
  • PK/PD of Dexamethasone in LPS-Challenged Rats
  • Cholesterol Esterification and Acute Lung Injury
Show more INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics